Cholecystokinin (CCK), formerly referred to as pancreozymins, is another hormone-like secretin used in the pancreas's stimulation. Secretin mainly stimulates the secretion of pancreatic juice, which contains pancreatic enzymes and acts on the gallbladder, which can assess gallbladder function. CCK increases pancreatic enzyme output and causes gallbladder contraction. Therefore, the CCK test can help to diagnose biliary tract diseases.
Cholecystokinin-cholescintigraphy (CCK-HIDA) is the gold standard test for evaluating patients for obstructive cholecystitis or biliary dyskinesia. The finding of an abnormal gallbladder ejection fraction (GBEF) could signal the presence of an array of disease entities, including biliary dyskinesia, chronic or acute cholecystitis, bile sludging, etc. The HIDA may also demonstrate a filling defect, which represents a likely stone lodged in the cystic duct. Cholecystectomy is the recommended approach for those with abnormal GBEF and abdominal pain.
GBEF is calculated as the flow of radioactive tracer that is ejected from the gallbladder. A GBEF of <35% is considered abnormal. Patients considered for CCK-HIDA are those presenting with functional biliary pain based on the Rome III criteria. Those who present with atypical pain may not need as HIDA as the presentation may be from other pathology.
2. The physician should make a note of the other medications taken by the patient.
3. Intravenous access: Before gaining intravenous access, the patient receives instruction regarding the procedure of the test. After this counseling session, the CCK will be injected through the vein and the imaging done over the patient's abdomen. During that time, the patient should remain still.
Abdominal pain is a frequent complaint and the reason many people present to emergency departments or clinics. Right upper quadrant pain is commonly associated with biliary diseases. Qualitative cholescintigraphy can evaluate gall bladder emptying.
Clinicians often employ CCK cholescintigraphy/HIDA when biliary pain presents with a RUQ ultrasound showing obvious gallstones or in a normal-appearing ultrasound in the setting of classic physical exam findings associated with biliary disease.
Chronic cholecystitis is clinically diagnosed by poor gallbladder contractility due to prolonged inflammation. HIDA helps diagnose not only the delayed emptying but also the impaired squeeze of the GB musculature.
When there is high clinical suspicion of a calculus obstruction, the HIDA scan without CCK helps demonstrate GB filling but not squeeze.
CCK-HIDA scan is used to diagnose or rule out the following potential diagnoses:
A GBEF of < 35% after a 3-minute infusion is considered abnormal. However, the symptoms of a few patients did not resolve after cholecystectomy. Previous studies show that those with such false positive GBEF received unnecessary cholecystectomy. All these findings confirm that the symptoms can be secondary to a non-biliary cause and that this procedure could yield definite false positives.
Various researchers, over the years, studied different doses and infusion times for the CCK test. The challenge of using this important test is to find the correct combination of dose and time, which provides the least variability. Following more robust studies, the Hepatobiliary Practice Guideline of the Society of Nuclear Medicine recommends that a 60-minute infusion of CCK at the rate of 0.02ug/kg to be considered the standard method where GBEF of >38% is normal.
Chronic cholecystitis is the diagnosis when the GBEF is 6%, with the infusion of 0.01 mcg/kg of CCK over 3 minutes. There is significant variability in the GBEF when using this technique since different doses, and infusion rates can yield false-positive results.
An abnormal response to CCK stimulation by the sphincter of Oddi is also observable in patients with irritable bowel syndrome.
Food intake is the major factor that interferes with this test. False positives arise based on the contracted state of the gallbladder in the presence of food.
Of note, patients who have been kept NPO for an extended period may have thicker bile, often referred to as sludge, which may affect the test results leading to false positives.
The test is usually safe; however, the patients undergoing the test should receive information regarding the necessary precautions.
Patients with abdominal pain and, generally, an ultrasound that shows gallstones often receive a referral to undergo CCK-HIDA scan. The patients must understand that this test will determine the functionality of their gall bladder. An abnormal GBEF of <35% confirms that a diagnosis of biliary dyskinesia, or with a filling defect that an obstructed cystic duct is present and cholecystectomy may relieve their symptoms. It is a good prediction for the successful resolution of symptoms following cholecystectomy. This procedure is tolerated well by the patients.
As the radioactive tracer may take some days exit from the bloodstream via urine or stool, the patients should increase the intake of water for a short period post-procedure.
Previously, clinicians used fatty meals to ascertain the status of gallbladder function, however, it had its limitations and did not give the same evidence as a 60-minute infusion of CCK gives. CCK- infusion method is substantiated and is better tolerated by patients, especially those with severe abdominal pain.
The CCK-cholescintigraphy test is useful in predicting the efficacy of cholecystectomy, and it is the gold standard for assessing gallbladder emptying and function. Effectively, the CCK-HIDA/scintigraphy can rule out functional obstruction of the cystic duct; this may be from biliary dyskinesia (failure of gallbladder contraction) or acalculous cholecystitis (sludging of bile). Patients with abnormal GBEF on CCK test, tend to have a complete resolution of their symptoms following cholecystectomy.
Despite all the guidelines and research, knowing the actual value of a GBEF in a diseased patient is not clear. All values used to define abnormal GBEF are based on healthy individuals. Therefore, it is the responsibility of clinicians to consider the larger picture while diagnosing biliary or gallbladder dyskinesia.
|||BURTON P,HARPER AA,HOWAT HT,SCOTT JE,VARLEY H, The use of cholecystokinin to test gall bladder function in man. Gut. 1960 Sep [PubMed PMID: 13689291]|
|||Richmond BK,DiBaise J,Ziessman H, Utilization of cholecystokinin cholescintigraphy in clinical practice. Journal of the American College of Surgeons. 2013 Aug [PubMed PMID: 23731969]|
|||Gokhale SM,Lokare S,Nemade P, Role of cholescintigraphy in management of acute acalculous cholecystitis. Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India. 2012 Oct; [PubMed PMID: 24019652]|
|||Littleton LT,Fileta BB,Massey R,Wood TI, Kinevac stability after reconstitution with sodium chloride injection USP, 0.9%. Journal of nuclear medicine technology. 2009 Mar; [PubMed PMID: 19223430]|
|||Law R,Lopez R,Costanzo A,Parsi MA,Stevens T, Endoscopic pancreatic function test using combined secretin and cholecystokinin stimulation for the evaluation of chronic pancreatitis. Gastrointestinal endoscopy. 2012 Apr; [PubMed PMID: 22281107]|
|||Ponce J,Pons V,Sopena R,Garrigues V,Ponce M,Ortiz V,Pertejo V, Quantitative cholescintigraphy and bile abnormalities in patients with acalculous biliary pain. European journal of nuclear medicine and molecular imaging. 2004 Aug; [PubMed PMID: 15029457]|
|||DiBaise JK,Richmond BK,Ziessman HA,Everson GT,Fanelli RD,Maurer AH,Ouyang A,Shamamian P,Simons RJ,Wall LA,Weida TJ,Tulchinsky M, Cholecystokinin-cholescintigraphy in adults: consensus recommendations of an interdisciplinary panel. Clinical nuclear medicine. 2012 Jan; [PubMed PMID: 22157031]|
|||Sorenson MK,Fancher S,Lang NP,Eidt JF,Broadwater JR, Abnormal gallbladder nuclear ejection fraction predicts success of cholecystectomy in patients with biliary dyskinesia. American journal of surgery. 1993 Dec; [PubMed PMID: 8273847]|